This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Investigators from multiple institutions conducted a retrospective analysis of reports made to the US Food and Drug Administration (FDA) to assess the rates of pregnancy-related adverse events associated with isotretinoin use before and after the 2006 implementation of the iPLEDGE program. iPLEDGE was meant to reduce fetal exposure to isotretinoin by requiring female patients of childbearing potential to have a negative pregnancy test and verify 2 forms of contraception monthly to obtain an isotretinoin prescription. iPLEDGE also requires prescribers to report to the FDA any pregnancies among isotretinoin users.
Investigators used the FDA …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Related Articles
Cited By...
- No citing articles found.